Literature DB >> 3676828

The effects of the aminopeptidase inhibitors amastatin and bestatin on angiotensin-evoked neuronal activity in rat brain.

J W Harding1, D Felix.   

Abstract

During a recent comparison of iontophoretically applied angiotensin II (AII) and angiotensin III (AIII) in the paraventricular nucleus of the rat, we observed that the response latency for AIII was much shorter than that for AII. This suggested that AII may have to be converted to AIII before it becomes active. To test this hypothesis we performed 3 experiments. (1) We examined the effects of bestatin, an aminopeptidase B inhibitor, on the activity of applied AII and AIII. (2) Next, we monitored the effects of amastatin, a specific aminopeptidase A inhibitor, on the action of co-applied AII or AIII. (3) And, finally, we examined the response to the aminopeptidase-resistant analog Sar1-AII, both applied alone and in combination with AII or AIII. Bestatin, while having no activity of its own, dramatically enhanced the actions of both AII and AIII. Amastatin, on the other hand, had little effect on AII's action and diminished or totally blocked AII-dependent activity. Like bestatin, amastatin had no effect alone. Sar1-AII reduced spontaneous activity of angiotensin-sensitive neurons and inhibited the actions of AII and AIII in a reversible manner. The same cells were also blocked by the recognized angiotensin antagonist Sar1, Ile8-AII. In total these results strongly support the notion that AII must be converted to AIII in the brain before it is activated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3676828     DOI: 10.1016/0006-8993(87)91474-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  The significance of brain aminopeptidases in the regulation of the actions of angiotensin peptides in the brain.

Authors:  Robert C Speth; Vardan T Karamyan
Journal:  Heart Fail Rev       Date:  2008-01-09       Impact factor: 4.214

Review 2.  Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions.

Authors:  Mathilde Keck; Reda Hmazzou; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2019-05-21       Impact factor: 5.369

3.  Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.

Authors:  S Zini; M C Fournie-Zaluski; E Chauvel; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 4.  Role of angiotensin III in hypertension.

Authors:  Annabelle Reaux-Le Goazigo; Xavier Iturrioz; Celine Fassot; Cedric Claperon; Bernard P Roques; Catherine Llorens-Cortes
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

Review 5.  Aminopeptidase A inhibitors as centrally acting antihypertensive agents.

Authors:  Laurence Bodineau; Alain Frugière; Yannick Marc; Cédric Claperon; Catherine Llorens-Cortes
Journal:  Heart Fail Rev       Date:  2008-01-03       Impact factor: 4.214

6.  Distinct Molecular Effects of Angiotensin II and Angiotensin III in Rat Astrocytes.

Authors:  Michelle A Clark; Chinh Nguyen; Hieu Tran
Journal:  Int J Hypertens       Date:  2013-02-14       Impact factor: 2.420

7.  Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Int J Hypertens       Date:  2012-06-26       Impact factor: 2.420

Review 8.  Aminopeptidase N in arterial hypertension.

Authors:  Robert S Danziger
Journal:  Heart Fail Rev       Date:  2007-11-16       Impact factor: 4.214

9.  Inhibition of Porcine Aminopeptidase M (pAMP) by the Pentapeptide Microginins.

Authors:  Glaucio Monteiro Ferreira; Thales Kronenberger; Éryka Costa de Almeida; Joseane Sampaio; Clélia Ferreira Terra; Ernani Pinto; Gustavo Henrique Goulart Trossini
Journal:  Molecules       Date:  2019-11-29       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.